Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
Nearly three out of four biopharmaceutical firms modified traditional protocols to adopt a form of decentralized studies – also known as virtual or siteless trials – in an effort to keep drug development programs on course during COVID-19. The strategy proved successful. Now, having gained a foothold in the biopharma industry, decentralized trials are poised to play a major role in drug development post-pandemic.
To execute decentralized research strategies, sponsors are turning to an integrated supply chain solution known as Direct-to-Patient Services. Direct-to-Patient Services allow patients to participate in clinical trials from their homes by providing them with study drugs and care where they live.
Download this eBook to learn about the integral role Direct-to-Patient Services play in the execution of decentralized trials and how sponsors can maximize these benefits to improve drug development.